CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases

• Published in: American journal of clinical pathology Vol. 129; no. 4; pp. 526 - 529
• Main Authors: Zhang, Jing, Sokal, Izabela, Peskind, Elaine R., Quinn, Joseph F., Jankovic, Joseph, Kenney, Christopher, Chung, Kathryn A., Millard, Steven P., Nutt, John G., Montine, Thomas J.
• Format: Journal Article
• Language: English
• Published: Chicago, IL American Society of Clinical Pathologists 01.04.2008
• Subjects: Aged; Alzheimer Disease - cerebrospinal fluid; Amyloid beta-Peptides; Apolipoproteins - cerebrospinal fluid; Apolipoproteins E - cerebrospinal fluid; beta 2-Microglobulin; Biological and medical sciences; Biomarkers - cerebrospinal fluid; Brain-Derived Neurotrophic Factor - cerebrospinal fluid; Cerebrospinal Fluid; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Diagnosis, Differential; Female; Humans; Interleukin-8 - cerebrospinal fluid; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Middle Aged; Neurology; Parkinson Disease - cerebrospinal fluid; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Peptide Fragments; Protein Precursors - cerebrospinal fluid; tau Proteins - cerebrospinal fluid; Vitamin D-Binding Protein - cerebrospinal fluid; Nervous system diseases; Alzheimer disease; Parkinson disease; Cerebrospinal fluid; Profile; Cerebral disorder; Anatomic pathology; Random forest algorithm; Analyte profile; Central nervous system disease; Biomarkers; Degenerative disease; Extrapyramidal syndrome
• ISSN: 0002-9173; 1943-7722
• DOI: 10.1309/W01Y0B808EMEH12L

The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) tau and decreased amyloid (A) beta42 have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): tau, brain-derived neurotrophic factor, interleukin 8, Abeta42, beta2-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.